Bronstein, Gewirtz & Grossman, LLC Is Investigating NovoCure Limited (NVCR) And Encourages Stockholders to Connect

NEW YORK CITY, NY / ACCESS Newswire / June 26, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of NovoCure Limited ("Novocure" or "the Company") (NASDAQ:NVCR). Investors who purchased Novocure securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NVCR.

Novocure Investigation Details

On June 18, 2026, NovoCure issued a press release "announc[ing] topline results today from its Phase 3 TRIDENT trial, which evaluated the initiation of Tumor Treating Fields (TTFields) therapy for newly diagnosed glioblastoma (GBM) at the start of chemoradiation (Early Start Arm) compared to initiating TTFields therapy during the subsequent maintenance phase of treatment (Maintenance Start Arm)." NovoCure reported that "[t]he trial did not demonstrate a statistically significant improvement in the primary endpoint of overall survival for the Early Start Arm compared to the Maintenance Start Arm." On this news, NovoCure's stock price fell $3.57 per share, or 20%, to close at $14.28 per share on June 18, 2026.

What's Next for Novocure Investors?

If you are aware of any facts relating to this investigation or purchased Novocure securities, you can assist this investigation by visiting the firm's site: bgandg.com/NVCR. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911

No Cost to Novocure Investors

We, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman, LLC for Novocure Securities Investigation?

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.

Contact Info

Peretz Bronstein, Esq. or Nathan Miller

Bronstein, Gewirtz & Grossman, LLC

917-590-0911 | [email protected]

Attorney advertising.

Prior results do not guarantee similar outcomes.

SOURCE: Bronstein, Gewirtz & Grossman, LLC